신경 바이오마커 시장 규모, 점유율, 동향 분석 보고서 : 용도별, 유형별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Neurological Biomarkers Market Growth & Trends:

The global neurological biomarkers market size is expected to reach USD 18.75 billion by 2030, expanding at a CAGR of 12.9% from 2025 to 2030, according to a new report by Grand View Research, Inc. Increased funding for R&D of neurological biomarkers to boost development of new drugs is expected to impel market growth. National Institute of Neurological Disorders and Stroke provides funding opportunities such as cooperative agreements & development grants for researchers conducting studies related to clinical validation, analytical validation, & biomarker discovery.

Biomarkers play a significant role in the development of drugs for the treatment of neurological diseases. In recent years, there has been a significant rise in investments in the R&D of treatments for neurological diseases. For instance, in December 2020, Target ALS-a nonprofit research foundation-announced research funding of USD 15 million for a project focused on the discovery of novel biomarkers for ALS, which is anticipated to accelerate market growth in the forecast period.

Availability of technologically advanced products such as Quanterix Simoa (single-molecule array), which is a digitized ELISA test with a high signal-to-noise ratio. This technology helps overcome blood-brain barrier issues associated with neurological disease-related biomarkers. Such technological advancements are expected to drive market growth. For instance, in January 2021, Abbott introduced the first rapid blood test for traumatic brain injury, including concussion. This test measures a particular protein that is found in the blood after a traumatic brain injury and can be used to rule out the need for CT scanning in case of negative test results.

Factors such as lack of awareness about such diagnostic products & their high cost and limited availability or absence of neurologists, especially in developing & underdeveloped countries, could affect the adoption of such biomarker-based diagnostic solutions. According to a World Federation of Neurology survey of 63/84 WHO member countries, the majority of neurologists in 31/63 countries worked in major cities. One neurologist was serving a population of about 6,240 to 4,750,000.

Neurological Biomarkers Market Report Highlights:

• In 2024, proteomic type accounted for the largest market share and is anticipated to maintain their dominance over the forecast period as these are essential for accurate diagnosis of disease onset and progression due to the careful detection of posttranslational modifications and protein signatures
• Parkinson's disease segment held the largest market share owing to rising incidence and increasing R&D activities.
• Based on end use, the research organizations and others segment dominated the neurological biomarkers market. Research organizations collaborating for the development of therapeutics for treating neurological disorders utilize biomarkers for assessing the drug tolerance.
• North America dominated the market owing to presence of market players with strong presence in the U.S. & Canada, and increasing government funding for the development of novel biomarkers
• Asia-Pacific is anticipated to witness significant growth over the forecast period owing to high adoption of technologically advanced diagnostic products in developed countries such as Japan & Australia and increasing adoption of these products in developing economies such as China and India.

Table of Contents

Chapter 1 Methodology And Scope

• 1.1 Market Segmentation And Scope
  • 1.1.1 Segment Definition
    • 1.1.1.1 Application Segment
    • 1.1.1.2 Type Segment
    • 1.1.1.3 End Use Segment
• 1.2 Regional Scope
• 1.3 Estimates And Forecast Timeline
• 1.4 Objectives
  • 1.4.1 Objective - 1
  • 1.4.2 Objective - 2
  • 1.4.3 Objective - 3
• 1.5 Research Methodology
• 1.6 Information Procurement
  • 1.6.1 Purchased Database
  • 1.6.2 Gvr's Internal Database
  • 1.6.3 Secondary Sources
  • 1.6.4 Primary Research
• 1.7 Information Or Data Analysis
  • 1.7.1 Data Analysis Models
• 1.8 Market Formulation & Validation
• 1.9 Model Details
  • 1.9.1 Commodity Flow Analysis
• 1.10 List Of Secondary Sources
• 1.11 List Of Abbreviations

Chapter 2 Executive Summary

• 2.1 Market Outlook
• 2.2 Application And Type Snapshot
• 2.3 End Use Snapshot
• 2.4 Competitive Landscape Snapshot

Chapter 3 Neurological Biomarkers Market Variables, Trends, And Scope

• 3.1 Neurological Biomarkers Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
• 3.2 Penetration And Growth Prospect Mapping
• 3.3 Pipeline Analysis
  • 3.3.1 Alzheimer's Disease
  • 3.3.2 Parkinson's Disease
  • 3.3.3 Multiple Sclerosis
  • 3.3.4 Autism Spectrum Disorder
• 3.4 Market Dynamics
  • 3.4.1 Market Driver Analysis
    • 3.4.1.1 Increasing Prevalence Of Neurological Diseases
    • 3.4.1.2 Technological Advancements
    • 3.4.1.3 Increased Funding For R&D In Biomarkers
  • 3.4.2 Market Restraint Analysis
    • 3.4.2.1 Lack Of Consumer Awareness
    • 3.4.2.2 Reimbursement Policies
• 3.5 Neurological Biomarkers: Market Analysis Tools
  • 3.5.1 Industry Analysis - Porter's
  • 3.5.2 Pestle Analysis

Chapter 4 Neurological Biomarkers Market: Segment Analysis, By Type, 2018 - 2030 (USD Million)

• 4.1 Neurological Biomarkers Market: Type Movement Analysis
  • 4.1.1 Genomic
    • 4.1.1.1 Genomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 4.1.2 Proteomic
    • 4.1.2.1 Proteomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 4.1.3 Metabolomic
    • 4.1.3.1 Metabolomic Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 4.1.5 Imaging
    • 4.1.5.1 Imaging Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 4.1.6 Others
    • 4.1.6.1 Others Neurological Biomarkers Market, 2018 - 2030 (USD Million)

Chapter 5 Neurological Biomarkers Market: Segment Analysis, By Application, 2018 - 2030 (USD Million)

• 5.1 Neurological Biomarkers Market: Application Movement Analysis
  • 5.1.1 Alzheimer's Disease
    • 5.1.1.1 Alzheimer's Disease Market, 2018 - 2030 (USD Million)
  • 5.1.2 Parkinson's Disease
    • 5.1.2.1 Parkinson's Disease Market, 2018 - 2030 (USD Million)
  • 5.1.3 Multiple Sclerosis
    • 5.1.3.1 Multiple Sclerosis Market, 2018 - 2030 (USD Million)
  • 5.1.4 Autism Spectrum Disorder
    • 5.1.4.1 Autism Spectrum Disorder Market, 2018 - 2030 (USD Million)
  • 5.1.5 Others
    • 5.1.5.1 Others Market, 2018 - 2030 (USD Million)

Chapter 6 Neurological Biomarkers Market: Segment Analysis, By End Use, 2018 - 2030 (USD Million)

• 6.1 Neurological Biomarkers Market: End Use Movement Analysis
  • 6.1.1 Research Organizations
    • 6.1.1.1 Research Organizations Market, 2018 - 2030 (USD Million)
  • 6.1.2 Pharma & Biotech Companies
    • 6.1.2.1 Pharma & Biotech Companies Market, 2018 - 2030 (USD Million)
  • 6.1.3 Clinical Diagnostics
    • 6.1.3.1 Clinical Diagnostics Market, 2018 - 2030 (USD Million)

Chapter 7 Neurological Biomarkers Market: Segment Analysis, By Region, 2018 - 2030 (USD Million)

• 7.1 Regional Market Snapshot
• 7.2 North America
  • 7.2.1 North America Neurological Biomarkers Market Estimates And Forecast, 2018 - 2030 (USD Million)
  • 7.2.2 U.S.
    • 7.2.2.1 U.S. Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.2.2.2 Key Country Dynamics
    • 7.2.2.3 Regulatory Framework
    • 7.2.2.4 Reimbursement Scenario
  • 7.2.3 Canada
    • 7.2.3.1 Canada Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.2.3.2 Key Country Dynamics
    • 7.2.3.3 Regulatory Framework
    • 7.2.3.4 Reimbursement Scenario
  • 7.2.4 Mexico
    • 7.2.4.1 Mexico Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.2.4.2 Key Country Dynamics
    • 7.2.4.3 Regulatory Framework
    • 7.2.4.4 Reimbursement Scenario
• 7.3 Europe
  • 7.3.1 Europe Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.3.2 Uk
    • 7.3.2.1 Uk Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.2.2 Key Country Dynamics
    • 7.3.2.3 Regulatory Framework
    • 7.3.2.4 Reimbursement Scenario
  • 7.3.3 Germany
    • 7.3.3.1 Germany Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.3.2 Key Country Dynamics
    • 7.3.3.3 Regulatory Framework
    • 7.3.3.4 Reimbursement Scenario
  • 7.3.4 Spain
    • 7.3.4.1 Spain Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.4.2 Key Country Dynamics
    • 7.3.4.3 Regulatory Framework
    • 7.3.4.4 Reimbursement Scenario
  • 7.3.5 France
    • 7.3.5.1 France Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.5.2 Key Country Dynamics
    • 7.3.5.3 Regulatory Framework
    • 7.3.5.4 Reimbursement Scenario
  • 7.3.6 Italy
    • 7.3.6.1 Italy Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.6.2 Key Country Dynamics
    • 7.3.6.3 Regulatory Framework
    • 7.3.6.4 Reimbursement Scenario
  • 7.3.7 Denmark
    • 7.3.7.1 Denmark Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.7.2 Key Country Dynamics
    • 7.3.7.3 Regulatory Framework
    • 7.3.7.4 Reimbursement Scenario
  • 7.3.8 Sweden
    • 7.3.8.1 Sweden Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.8.2 Key Country Dynamics
    • 7.3.8.3 Regulatory Framework
    • 7.3.8.4 Reimbursement Scenario
  • 7.3.9 Norway
    • 7.3.9.1 Norway Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.3.9.2 Key Country Dynamics
    • 7.3.9.3 Regulatory Framework
    • 7.3.9.4 Reimbursement Scenario
• 7.4 Asia Pacific
  • 7.4.1 Asia-Pacific Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.4.2 Japan
    • 7.4.2.1 Japan Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.2.2 Key Country Dynamics
    • 7.4.2.3 Regulatory Framework
    • 7.4.2.4 Reimbursement Scenario
  • 7.4.3 China
    • 7.4.3.1 China Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.3.2 Key Country Dynamics
    • 7.4.3.3 Regulatory Framework
    • 7.4.3.4 Reimbursement Scenario
  • 7.4.4 India
    • 7.4.4.1 India Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.4.2 Key Country Dynamics
    • 7.4.4.3 Regulatory Framework
    • 7.4.4.4 Reimbursement Scenario
  • 7.4.5 South Korea
    • 7.4.5.1 South Korea Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.5.2 Key Country Dynamics
    • 7.4.5.3 Regulatory Framework
    • 7.4.5.4 Reimbursement Scenario
  • 7.4.6 Thailand
    • 7.4.6.1 Thailand Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.6.2 Key Country Dynamics
    • 7.4.6.3 Regulatory Framework
    • 7.4.6.4 Reimbursement Scenario
  • 7.4.7 Australia
    • 7.4.7.1 Australia Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.4.7.2 Key Country Dynamics
    • 7.4.7.3 Regulatory Framework
    • 7.4.7.4 Reimbursement Scenario
• 7.5 Latin America
  • 7.5.1 Latin America Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.5.2 Brazil
    • 7.5.2.1 Brazil Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.5.2.2 Key Country Dynamics
    • 7.5.2.3 Regulatory Framework
    • 7.5.2.4 Reimbursement Scenario
  • 7.5.3 Argentina
    • 7.5.3.1 Argentina Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.5.3.2 Key Country Dynamics
    • 7.5.3.3 Regulatory Framework
    • 7.5.2.4 Reimbursement Scenario
• 7.6 MEA
  • 7.6.1 MEA Neurological Biomarkers Market, 2018 - 2030 (USD Million)
  • 7.6.2 South Africa
    • 7.6.2.1 South Africa Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.6.2.2 Key Country Dynamics
    • 7.6.2.3 Regulatory Framework
    • 7.6.2.4 Reimbursement Scenario
  • 7.6.3 Saudi Arabia
    • 7.6.3.1 Saudi Arabia Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.6.3.2 Key Country Dynamics
    • 7.6.3.3 Regulatory Framework
    • 7.6.3.4 Reimbursement Scenario
  • 7.6.4 UAE
    • 7.6.4.1 UAE Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.6.4.2 Key Country Dynamics
    • 7.6.4.3 Regulatory Framework
    • 7.6.2.4 Reimbursement Scenario
  • 7.6.5 Kuwait
    • 7.6.5.1 Kuwait Neurological Biomarkers Market, 2018 - 2030 (USD Million)
    • 7.6.5.2 Key Country Dynamics
    • 7.6.5.3 Regulatory Framework
    • 7.6.5.4 Reimbursement Scenario

Chapter 8 Neurological Biomarkers Market: Competitive Analysis

• 8.1 Company Categorization
• 8.2 Strategy Mapping
  • 8.2.1 New Product Launch
  • 8.2.2 Partnerships
  • 8.2.3 Acquisition
  • 8.2.4 Collaboration
  • 8.2.5 Funding
• 8.3 Company Market Share Analysis, 2022
• 8.4 Company Profiles
  • 8.4.1 Abbott
    • 8.4.1.1 Company Overview
    • 8.4.1.2 Financial Performance
    • 8.4.1.3 Product Benchmarking
    • 8.4.1.4 Strategic Initiatives
  • 8.4.2 Johnson & Johnson Services, Inc.
    • 8.4.2.1 Company Overview
    • 8.4.2.2 Financial Performance
    • 8.4.2.3 Product Benchmarking
    • 8.4.2.4 Strategic Initiatives
  • 8.4.3 Bio-Rad Laboratories, Inc.
    • 8.4.3.1 Company Overview
    • 8.4.3.2 Financial Performance
    • 8.4.3.3 Product Benchmarking
    • 8.4.3.4 Strategic Initiatives
  • 8.4.4 Alseres Pharmaceuticals, Inc.
    • 8.4.4.1 Company Overview
    • 8.4.4.2 Product Benchmarking
  • 8.4.5 Banyan Biomarkers, Inc.
    • 8.4.5.1 Company Overview
    • 8.4.5.2 Product Benchmarking
    • 8.4.5.3 Strategic Initiatives
  • 8.4.6 Rules-Based Medicine
    • 8.4.6.1 Company Overview
    • 8.4.6.2 Financial Performance
    • 8.4.6.3 Product Benchmarking
    • 8.4.6.4 Strategic Initiatives
  • 8.4.7 Thermo Fisher Scientific, Inc.
    • 8.4.7.1 Company Overview
    • 8.4.7.2 Financial Performance
    • 8.4.7.3 Product Benchmarking
    • 8.4.7.4 Strategic Initiatives
  • 8.4.8 Diagenic Asa
    • 8.4.8.1 Company Overview
    • 8.4.8.2 Product Benchmarking
  • 8.4.9 Merck & Co., Inc.
    • 8.4.9.1 Company Overview
    • 8.4.9.2 Financial Performance
    • 8.4.9.3 Product Benchmarking
    • 8.4.9.4 Strategic Initiatives
  • 8.4.10 Quanterix
    • 8.4.10.1 Company Overview
    • 8.4.10.2 Product Benchmarking
    • 8.4.10.3 Strategic Initiatives